112 related articles for article (PubMed ID: 38740380)
1. Therapeutic Choices in Patients with Ph-Positive Chronic Myelogenous Leukemia In Mexico in the Era of Tyrosine Kinase Inhibitors: Stem Cell Transplantation or Tyrosine Kinase Inhibitors? Fifteen Years Later.
Max RN; Daniela SB; Moisés M GP; Edgar J HF; Merittzel A MR; María de L PM; Juan C OG; Guillermo J RD; Guillermo J RA
Rev Invest Clin; 2024; 76(2):91-96. PubMed ID: 38740380
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Pretransplant Use of Tyrosine Kinase Inhibitors on Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia - A Single-institution Retrospective Study.
Fujita S; Kasahara H; Kato J; Koda Y; Shiroshita K; Yamaguchi K; Okayama M; Abe R; Kikuchi T; Shimizu T; Mori T; Kataoka K; Okamoto S
Intern Med; 2024 Jun; 63(11):1549-1562. PubMed ID: 37899244
[TBL] [Abstract][Full Text] [Related]
3. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
Xu L; Zhu H; Hu J; Wu D; Jiang H; Jiang Q; Huang X
Front Med; 2015 Sep; 9(3):304-11. PubMed ID: 26100855
[TBL] [Abstract][Full Text] [Related]
4. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
Egan DN; Beppu L; Radich JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.
Nair AP; Barnett MJ; Broady RC; Hogge DE; Song KW; Toze CL; Nantel SH; Power MM; Sutherland HJ; Nevill TJ; Abou Mourad Y; Narayanan S; Gerrie AS; Forrest DL
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1437-44. PubMed ID: 25865648
[TBL] [Abstract][Full Text] [Related]
6. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
Wright MP; Shepherd JD; Barnett MJ; Nantel SH; Sutherland HJ; Toze CL; Hogge DE; Nevill TJ; Song KW; Abou Mourad YR; Narayanan S; Power MM; Smith CA; Forrest DL
Biol Blood Marrow Transplant; 2010 May; 16(5):639-46. PubMed ID: 20005967
[TBL] [Abstract][Full Text] [Related]
7. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?
Maziarz RT
Curr Opin Hematol; 2008 Mar; 15(2):127-33. PubMed ID: 18300759
[TBL] [Abstract][Full Text] [Related]
8. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study.
DeFilipp Z; Ancheta R; Liu Y; Hu ZH; Gale RP; Snyder D; Schouten HC; Kalaycio M; Hildebrandt GC; Ustun C; Daly A; Ganguly S; Inamoto Y; Litzow M; Szer J; Savoie ML; Hossain N; Kharfan-Dabaja MA; Hamadani M; Reshef R; Bajel A; Schultz KR; Gadalla S; Gerds A; Liesveld J; Juckett MB; Kamble R; Hashmi S; Abdel-Azim H; Solh M; Bacher U; Lazarus H; Olsson R; Cahn JY; Grunwald MR; Savani BN; Yared J; Rowe JM; Cerny J; Chaudhri NA; Aljurf M; Beitinjaneh A; Seo S; Nishihori T; Hsu JW; Ramanathan M; Alyea E; Popat U; Sobecks R; Saber W
Biol Blood Marrow Transplant; 2020 Mar; 26(3):472-479. PubMed ID: 31669399
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic progenitor cell transplantation for the treatment of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors: lessons learned to date.
Giralt S
Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 3():S102-4. PubMed ID: 17382018
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?
Ruiz-Argüelles GJ; Tarin-Arzaga LC; Gonzalez-Carrillo ML; Gutierrez-Riveroll KI; Rangel-Malo R; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Gómez-Almaguer D; Giralt S
Bone Marrow Transplant; 2008 Jul; 42(1):23-8. PubMed ID: 18612313
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party.
Radujkovic A; Dietrich S; Blok HJ; Nagler A; Ayuk F; Finke J; Tischer J; Mayer J; Koc Y; Sorà F; Passweg J; Byrne JL; Jindra P; Veelken JH; Socié G; Maertens J; Schaap N; Stadler M; Itälä-Remes M; Tholouli E; Arat M; Rocha V; Ljungman P; Yakoub-Agha I; Kröger N; Chalandon Y
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2008-2016. PubMed ID: 31271884
[TBL] [Abstract][Full Text] [Related]
12. [Second-generation tyrosine kinase inhibitors combined with allogeneic hematopoietic stem cell transplant for Philadelphia chromosome positive leukemia].
Yu X; Li C; Wu X; Ye L; Liu H; Ma C; Ma J; Gu C; Wu D
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):129-33. PubMed ID: 24606654
[TBL] [Abstract][Full Text] [Related]
13. Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Leukemia: 25 Years' Experience at Gustave Roussy Cancer Campus.
Chamseddine AN; Willekens C; De Botton S; Bourhis JH
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S129-40. PubMed ID: 26297265
[TBL] [Abstract][Full Text] [Related]
14. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
Breccia M; Palandri F; Iori AP; Colaci E; Latagliata R; Castagnetti F; Torelli GF; Usai S; Valle V; Martinelli G; Rosti G; Foà R; Baccarani M; Alimena G
Leuk Res; 2010 Feb; 34(2):143-7. PubMed ID: 19481800
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukemia-transplantation in the tyrosine kinase era.
Innes AJ; Apperley JF
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1037-53. PubMed ID: 25459178
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic haematopoietic cell transplantation for chronic myeloid leukaemia in Switzerland in the face of rapid development of effective drugs.
Heim D; Baldomero H; Medinger M; Masouridi-Levrat S; Schanz U; Nair G; Güngör T; Halter J; Passweg JR; Chalandon Y;
Swiss Med Wkly; 2024 May; 154():3754. PubMed ID: 38749067
[TBL] [Abstract][Full Text] [Related]
17. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
18. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
[TBL] [Abstract][Full Text] [Related]
19. [Advances in Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia--Review].
Chen XP; Cao ZR; Hu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1334-1338. PubMed ID: 31418403
[TBL] [Abstract][Full Text] [Related]
20. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.
Jabbour E; Cortes J; Santos FP; Jones D; O'Brien S; Rondon G; Popat U; Giralt S; Kebriaei P; Jones RB; Kantarjian H; Champlin R; de Lima M
Blood; 2011 Mar; 117(13):3641-7. PubMed ID: 21156844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
